Weight management program for kidney transplant candidates with obesity
Official title: Obesity Management for Kidney TRANSPLANTation: a Vanguard Study for an Innovative Randomized Controlled Trial, Embedded in Routine Care (OK-TRANSPLANT 2)
Run by Western University, Canada · NCT06396416 · Data updated 2026-11-12
This study is testing whether a virtual weight management program can help adults with obesity and kidney disease who are waiting for a transplant lose weight more effectively than their usual care.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Western University, Canada Academic / other |
| Locations | 1 site (London, Ontario) |
| Status | Recruiting |
| Started | September 26, 2024 |
| Main results expected | September 30, 2026 |
| Study ends | December 2026 |
| Registry record updated | June 29, 2026 |
| Trial ID | NCT06396416 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 years or older with a BMI greater than 35 kg/m² and a significant risk of end-stage kidney disease.
✕Probably not a fit
Patients who have type 1 diabetes or known contraindications to GLP-1 receptor agonists will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
OK-TRANSPLANT 2 is a pilot study designed to evaluate the feasibility of a virtual weight management program for adults with obesity and high-risk chronic kidney disease (CKD) who are seeking kidney transplantation. Participants will be randomized to either receive coaching on weight management using GLP-1 receptor agonists or continue with their usual care. The study aims to address the challenges of weight loss in this population, which is often complicated by dietary restrictions and functional impairments. By assessing recruitment and trial processes, this study will lay the groundwork for a larger randomized controlled trial.
Why it matters
Potential benefit: If successful, this study could improve access to kidney transplantation for patients with obesity and CKD by providing effective weight management strategies.
How similar studies have gone: While weight management in CKD patients has been explored, the specific use of GLP-1 receptor agonists in this context is novel and has not been extensively tested in dedicated trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years or older * BMI; 35 kg/m\^2 * 10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis Exclusion Criteria: * Known contraindication to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, hypersensitivity) * Type 1 diabetes * No access to semaglutide via drug coverage * Pregnant, breastfeeding or planning to become pregnant * Currently in a GLP-1RA or GLP-1RA/GIP study or planning to be in one
Where it's running
-
London Health Sciences Centre
London, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Kristin K Clemens, MD, MSc — St. Joseph's Health Care London
- Study coordinator: Heather LaPier, BSc
- Email: heather.lapier@sjhc.london.on.ca
- Phone: 519-646-6100
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating nutritional and environmental factors in elderly health
This study is trying to find out how nutrition and the environment affect the health of older people living in Nanshan to help prevent diseases like high blood pressure and diabetes.
-
Observational look at how Kremezin works in adults with advanced chronic kidney disease
This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.